ZIA CP010144-10376 (ZIA) | |||
---|---|---|---|
Title | Pilot Study: Collection, Analysis of Human Ovarian Surface Epithelial Cells | ||
Institution | NCI, Bethesda, MD | ||
Principal Investigator | Wentzensen, Nicolas | NCI Program Director | N/A |
Cancer Activity | N/A | Division | DCEG |
Funded Amount | $29,937 | Project Dates | 00/00/0000 - 00/00/0000 |
Fiscal Year | 2017 | Project Type | Intramural |
Research Topics w/ Percent Relevance | Cancer Types w/ Percent Relevance | ||
Biochemical Epidemiology (45.0%) Cancer (100.0%) |
Ovarian Cancer (50.0%) Uterine (35.0%) |
||
Research Type | |||
Cancer-Related Biology
Endogenous Factors in the Origin and Cause of Cancer |
|||
Abstract | |||
"""We are systematically assessing the prevalence of molecular markers in ovarian tissues that are collected at the time of hysterectomy for non-malignant conditions. The collection of ovarian surface epithelial (OSE) cells will be via a novel laparoscopically deployed cytobrush to collect the cells, prior to removing the ovaries from the pelvis (minimizing handling-relate loss of epithelium, and prior to vascular ligation (minimizing ischemia-related tissue changes). Our scientific hypothesis in this methods-oriented proposal is that etiologically-relevant silent molecular lesions will be more prevalent among women with specific epidemiologic risk factors for ovarian cancer than in women who lack those risk factors. Preliminary data document that this procedure produces larger numbers of OSE cells from which high-quality DNA and RNA have been extracted. Pilot evaluation of proteomic expression arrays and oligonucleotide expression arrays have been performed and demonstrate that satisfactory reagents have been obtained. More than 90 OSE samples have been collected, along with specimens from the endometrium and the Fallopian tube mucosa (the latter obtained via a novel, special endoscopic procedure developed by our collaborator Richard Guido from Magee Women's Hospital, Pittsburgh). The specimen collection has been expanded to include <i>BRCA1/2</i> mutation carriers, and women with overt ovarian cancer. The laboratory work has now begun with methylation arrays of these various tissues, soon to be followed by and miRNA profiling of these samples.""" |